

Medibio Limited (ASX: MEB)

Date: 22 December 2015

Medibio enters into MOU with Medtronic

Medibio Limited has entered into a non-binding memorandum of understanding (MOU) with Medtronic. Medtronic is a wholly owned subsidiary of Medtronic plc., listed on the New York Stock Exchange, NYSE: MDT.

The non-binding MOU provides a framework under which Medibio and Medtronic will enter discussions around a proposed strategic agreement covering business opportunities and synergies across both companies.

ABOUT MEDIBIO LIMITED

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress, and other mental health disorders. Based on research conducted over 15 years, initiated at the University of Western Australia, this test utilizes patented circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure of mental wellbeing to assist in a clinical diagnosis. The technology currently provides the first evidence based quantitative diagnostic test for mental health disorders in the corporate and consumer markets. Studies by Johns Hopkins University School of Medicine and the Ottawa University among others to validate the clinical utility of the test will potentially enable Medibio's technology to be the first FDA approved, objective, evidence based approach to the diagnosis mental health disorders for the medical industry. Located in Sydney, NSW, Medibio is listed on the Australian Stock Exchange.

Medibio.

ABOUT MEDTRONIC

Medtronic plc. (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services, and solutions companies - alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals, and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare *Further, Together*.

Further Information:

Website: www.medibio.com.au

www.medtronic.com

Medibio Shareholder Enquiries to:

Kris Knauer
CEO and Director Medibio Limited
kris.knauer@medibio.com.au
T: +61 (0)411 885979

Medibio Media Enquiries to:

Peter Taylor
NWR Communications
Peter@nwrcommunications.com.au
T: +61 (0)412 036 231